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The inherited disorders of haemoglobin are the commonest
monogenic diseases. It has been estimated that over 300 000
babies are born each year with one of these conditions, either
sickle-cell disease or severe forms of thalassaemia.1 Normal
adult haemoglobin (HbA) consists of two a- and two b-globin
chains (a2b2), each with an associated heme group, which are
regulated by duplicated HBA1 genes and a single HBB gene,
respectively. Sickle-cell haemoglobin (HbS) results from a single
point mutation at position 6 in the HBB gene that causes the sub-
stitution of glutamic acid for valine in the b-globin chain. In con-
ditions of reduced oxygen tension, this leads to polymerisation, a
change of shape of the red blood cells, and hence to chronic
anaemia, acute painful crises due to blockage of small vessels,
and often to progressive damage to multiple organs, including
the brain, kidneys, lungs, bones and the cardiovascular system.2
These complications are almost entirely restricted to those with
sickle-cell anaemia, i.e., individuals who have inherited the sickle-
cell mutation from both parents (SS); heterozygous carriers, who
have inherited a single copy of the gene (AS), are asymptomatic,
except in conditions of exceptional hypoxia.
While the clinical severity of sickle-cell disease has been clearly
described, its clinical course can be extremely variable and diffi-
cult to anticipate.3 This is true for sickle-cell anaemia, as well as
for other sickle-cell disorders such as HbSC disease or HbS
b-thalassaemia, and has important implications for the develop-
ment of procedures for the prevention and treatment of these dis-
orders. Although a few genes have been identified as modifiers of
the clinical course of sickle-cell disease, much work remains to be
done in this important field. In contrast, the sickle-cell trait (AS)
offers a very high degree of protection against infection with
Plasmodium falciparum malaria.4 Recently, however, although
this observation has been widely confirmed, it has been found
that parasite-infected blood from sickle-cell heterozygotes is
several times more infectious to the Anopheles vector than that
of normal subjects.5 This suggests, of course, that the advantage
of HbS heterozygotes is not only balanced by the cost of potential
homozygous offspring but also by that of increasedmalaria trans-
mission to the general population.
There is still some doubt about the origins of the sickle-cell
mutation and where it arose for the first time. Although the
hypothesis of five independent origins, four in sub-Saharan
Africa (named Bantu, Benin, Cameroon and Senegal) and one in
the Middle East and India (Arab-India) is almost universally
accepted, both early and recent work supported the alternative
hypothesis of a single origin.6,7 Significant differences in the
level of foetal haemoglobin (HbF) between the sub-Saharan
African haplotypes and the Asian might suggest that the sickle-
cell mutation has arisen at least twice. While the Arab-India
haplotype is usually described as associated with a milder clinical
course of the disease, growing evidence indicates that its severity
might have been underestimated.8,9
Sickle-cell disease is highly prevalent in sub-Saharan Africa,
and parts of the Mediterranean region, the Middle East and the
Indian subcontinent. Estimates suggest that 75% of annual con-
ceptions with sickle-cell anaemia occur in sub-Saharan Africa and
demographic projections support the fact that this share is likely
to grow further in coming decades.10 The sickle-cell mutation was
later spread to the Americas and western Europe through the
trade of African slaves, and over recent decades tomost countries
worldwide due to increasing international movements. Universal
newborn screening programmes were implemented more than a
decade ago in the UK and across all states in the USA.11
Meanwhile, the implementation of such national programmes
has not been possible in any African country, nor in India (despite
recent progress, especially in the States of Gujarat, Maharashtra
and Chhattisgarh), where they would have had the most impact.
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Clearly, much work requires to be done towards the prevention
and management of sickle-cell disease. As regards to early man-
agement, neonatal screening followed by prophylactic vaccin-
ation and antibiotics has led to a dramatic decrease in the
mortality in early life in many high-income countries.12 There is
now increasing evidence that a similar approach would be of
great value in low- and middle-income countries.13 Regarding
prenatal diagnosis and termination of pregnancy, this has been
much less widely applied than in the case of thalassaemia. At
least in part, this is undoubtedly due to the ethical difficulties of
counselling due to uncertainties about the future clinical course
of any particular patient. Clinical trials of hydroxyurea have now
shown that the drug is of definite value both in adult and paedi-
atric populations.14 Bone marrow transplantation has also been
fairly limited for this disease, partly because of the paucity of
donors and again because of the risks involved and the uncertain-
ties in the prognosis for the disease. Nevertheless, there have been
genuine improvements in the management of sickle-cell disease
and it is critical that these approaches become available to the
low- and middle-income countries.
Although WHO recognised sickle-cell disease as a worldwide
public health issue in 2006 and a resolution on the prevention
and management of birth defects, including those resulting
from sickle-cell disease, was adopted a couple of years later at
the 63rd World Health Assembly, a public health agenda to pre-
vent and control this disease is still lacking in most countries of
high prevalence. As recently highlighted for infectious diseases
such as Ebola and HIV, there is an urgent need for better health-
care systems in low- and middle-income countries, particularly in
sub-Saharan Africa. While events and celebrations organised for
the World Sickle Cell Day on 19 June will hopefully contribute to
raise awareness about this disease, such overall improvements
in public health access and care are a prerequisite to improve
the survival and quality of life of patients with sickle-cell disease
in tropical regions.
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